尼达尼布联合培美曲塞和顺铂治疗初治晚期恶性胸膜间皮瘤的3期试验
LUME-Meso 3期试验在27国120中心纳入458例不可切除上皮样恶性胸膜间皮瘤初治患者,随机接受培美曲塞+顺铂联合尼达尼布或安慰剂。
要点
- 尼达尼布联合标准化疗未改善初治恶性胸膜间皮瘤的无进展生存期。
- 两组最常见≥3级不良事件均为中性粒细胞减少(32% vs 24%)。
- 严重不良事件发生率尼达尼布组44%、安慰剂组39%,无意外安全性信号。
核心结论
- 3期部分的主要无进展生存期终点未达到,2期结果未获证实。
- 未报告意外安全性发现。
研究设计与样本
- 双盲、随机、安慰剂对照3期试验,在27国120个学术医学中心和社区诊所进行。
- 纳入458例不可切除上皮样恶性胸膜间皮瘤初治成人(≥18岁,ECOG 0-1),1:1随机至尼达尼布组(n=229)或安慰剂组(n=229)。
- 治疗为最多6个21天周期培美曲塞(500 mg/m2)加顺铂(75 mg/m2)第1天,第2-21天尼达尼布(200 mg每日两次)或匹配安慰剂;无进展者接受维持治疗。
- 主要终点为意向治疗人群研究者评估的无进展生存期(mRECIST)。
主要发现
- 最常见≥3级不良事件为中性粒细胞减少:尼达尼布组73例(32%),安慰剂组54例(24%)。
- 严重不良事件:尼达尼布组99例(44%),安慰剂组89例(39%);唯一在任一组≥5%发生的严重不良事件为肺栓塞(13例[6%] vs 7例[3%])。
临床怎么用
- 不推荐在初治不可切除上皮样恶性胸膜间皮瘤中常规联合尼达尼布与培美曲塞+顺铂。
- 联合方案需关注中性粒细胞减少和肺栓塞等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso trial, which aimed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma. METHODS: This double-blind, randomised, placebo-controlled phase 3 trial was done at 120 academic medical centres and community clinics in 27 countries across the world. Chemotherapy-naive adults (aged ≥18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an independently verified random number-generating system to receive up to six 21-day cycles of pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on day 1, then nintedanib (200 mg twice daily) or matched placebo on days 2-21. Patients without disease progression after six cycles received nintedanib or placebo maintenance on days 1-21 of each cycle. The primary endpoint was progression-free survival (investigator-assessed according to mRECIST) in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of their assigned study drug. This study is registered with ClinicalTrials.gov, number NCT01907100. FINDINGS: Between April 14, 2016, and Jan 5, 2018, 541 patients were screened and 458 were randomly assigned to either the nintedanib group (n=229) or the placebo group (n=229). Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. After 250 events, progression-free survival was not different between the nintedanib group (median 6·8 months [95% CI 6·1-7·0]) and the placebo group (7·0 months [6·7-7·2]; HR 1·01 [95% CI 0·79-1·30], p=0·91). The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%] in the placebo group). Serious adverse events were reported in 99 (44%) patients in the nintedanib group and 89 (39%) patients in the placebo group. The only serious adverse event occurring in at least 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]). INTERPRETATION: The primary progression-free survival endpoint of the phase 3 part of LUME-Meso was not met and phase 2 findings were not confirmed. No unexpected safety findings were reported. FUNDING: Boehringer Ingelheim.
引用
- Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019. PMID: 31103412. doi:10.1016/S2213-2600(19)30139-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。